Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to ...

Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Inflammatix has secured the FDA’s blessing for its in vitro diagnostic system, aimed at rapidly profiling the body’s response ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Clinical research tech firm Advarra has unveiled a new digital solution meant to help speed up study starts and facilitate ...

Many of the most devastating infectious diseases are caused by RNA viruses and Model Medicines is working on one compound to ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...